

Michael T Tetzlaff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1388900/publications.pdf>

Version: 2024-02-01

168
papers

15,409
citations

61945

43
h-index

20343

116
g-index

173
all docs

173
docs citations

173
times ranked

22194
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018, 359, 97-103.	6.0	3,126
2	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	13.7	1,421
3	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 202-216.	7.7	1,158
4	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016, 6, 827-837.	7.7	785
5	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	689
6	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654.	15.2	592
7	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. <i>Nature Medicine</i> , 2018, 24, 1804-1808.	15.2	521
8	Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 6582-6592.	3.2	493
9	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. <i>Science</i> , 2021, 374, 1632-1640.	6.0	369
10	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. <i>Nature</i> , 2016, 532, 250-254.	13.7	290
11	Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1692-1697.	3.3	237
12	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 181-193.	5.1	233
13	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. <i>Cancer Discovery</i> , 2019, 9, 628-645.	7.7	231
14	Cobomarsen, an oligonucleotide inhibitor of miR-155, coordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. <i>British Journal of Haematology</i> , 2018, 183, 428-444.	1.2	219
15	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	15.2	216
16	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 158-176.	0.7	186
17	Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. <i>Clinical Cancer Research</i> , 2014, 20, 5537-5546.	3.2	169
18	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155

#	ARTICLE	IF	CITATIONS
19	Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with <i>BRAF</i> V600 Mutations. <i>Clinical Cancer Research</i> , 2014, 20, 5527-5536.	3.2	145
20	The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. , 2020, 8, e000155.		140
21	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 508-515.	0.3	138
22	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 1861-1868.	0.6	135
23	Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 688-696.	0.7	126
24	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	1.7	120
25	Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. , 2018, 6, 14.		118
26	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. <i>Nature Communications</i> , 2017, 8, 607.	5.8	109
27	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. <i>BMC Medicine</i> , 2016, 14, 168.	2.3	106
28	Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 5553-5563.	3.2	96
29	Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features. <i>American Journal of Dermatopathology</i> , 2017, 39, 121-129.	0.3	96
30	Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators. <i>OncImmunology</i> , 2017, 6, e1306618.	2.1	78
31	IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 860-865.	1.6	76
32	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 1025-1035.	1.6	70
33	Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma. <i>Modern Pathology</i> , 2013, 26, 1153-1160.	2.9	67
34	Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. <i>Journal of Pathology</i> , 2016, 240, 84-95.	2.1	63
35	Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. <i>International Journal of Dermatology</i> , 2014, 53, 376-384.	0.5	62
36	A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 6429-6442.	3.2	61

#	ARTICLE	IF	CITATIONS
37	Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesions. <i>Modern Pathology</i> , 2016, 29, 832-843.	2.9	55
38	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>Oncolimmunology</i> , 2016, 5, e1136044.	2.1	55
39	Melanoma arising in association with blue nevus: a clinical and pathologic study of 24 cases and comprehensive review of the literature. <i>Modern Pathology</i> , 2014, 27, 1468-1478.	2.9	54
40	A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. , 2016, 4, 55.		50
41	Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. <i>Oncolimmunology</i> , 2017, 6, e1361097.	2.1	50
42	PARP Inhibition Suppresses GR β -MYCN β -CDK5 β -RB1 β -E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6839-6851.	3.2	50
43	Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. <i>Clinical Cancer Research</i> , 2017, 23, 2093-2104.	3.2	48
44	Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy—Report of 2 patients. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1080-1086.	0.7	48
45	Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 100-105.	1.6	46
46	Prognostic factors for local recurrence, metastasis and survival for sebaceous carcinoma of the eyelid: observations in 100 patients. <i>British Journal of Ophthalmology</i> , 2019, 103, 980-984.	2.1	46
47	Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries. <i>Cancer</i> , 2015, 121, 1993-2003.	2.0	45
48	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. <i>Oncolimmunology</i> , 2017, 6, e1321187.	2.1	45
49	Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries. <i>Cancer Medicine</i> , 2015, 4, 1440-1447.	1.3	44
50	Multiplex Immunofluorescence Assays. <i>Methods in Molecular Biology</i> , 2020, 2055, 467-495.	0.4	44
51	Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. <i>Human Pathology</i> , 2015, 46, 558-569.	1.1	43
52	Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. <i>Human Pathology</i> , 2015, 46, 1101-1110.	1.1	43
53	miR-200c/Bmi-1 axis and epithelial-mesenchymal transition contribute to acquired resistance to $\text{BRAF}^{\text{V600E}}$ inhibitor treatment. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 431-441.	1.5	41
54	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma. <i>JAMA Oncology</i> , 2016, 2, 1056.	3.4	41

#	ARTICLE	IF	CITATIONS
55	Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes. <i>Modern Pathology</i> , 2019, 32, 396-404.	2.9	41
56	Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 1161-1166.	0.7	40
57	Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations. <i>Clinical Cancer Research</i> , 2019, 25, 1280-1290.	3.2	39
58	Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2887-2895.	1.9	38
59	Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 764-773.	0.7	38
60	Clinicopathological features and clinical outcomes associated with TP53 and BRAF ^N mutations in cutaneous melanoma patients. <i>Cancer</i> , 2017, 123, 1372-1381.	2.0	36
61	Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow Resident Melanoma CTCs. <i>Cancer Research</i> , 2018, 78, 5349-5362.	0.4	36
62	Distinct Pathways in the Pathogenesis of Sebaceous Carcinomas Implicated by Differentially Expressed MicroRNAs. <i>JAMA Ophthalmology</i> , 2015, 133, 1109.	1.4	33
63	Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). <i>Journal of Neuro-Oncology</i> , 2019, 142, 499-509.	1.4	33
64	Tisotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. <i>Cancer Discovery</i> , 2021, 11, 1996-2013.	7.7	32
65	Ambiguous Melanocytic Tumors in a Tertiary Referral Center. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1783-1796.	2.1	31
66	Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. , 2020, 8, e000960.		31
67	Update on Merkel Cell Carcinoma. <i>Head and Neck Pathology</i> , 2018, 12, 31-43.	1.3	30
68	PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma. , 2019, 60, 2388.		30
69	Danger is only skin deep: aggressive epidermal carcinomas. An overview of the diagnosis, demographics, molecular-genetics, staging, prognostic biomarkers, and therapeutic advances in Merkel cell carcinoma. <i>Modern Pathology</i> , 2020, 33, 42-55.	2.9	30
70	Toward a Molecular-Genetic Classification of Spitzoid Neoplasms. <i>Clinics in Laboratory Medicine</i> , 2017, 37, 431-448.	0.7	29
71	Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis. <i>JAMA Dermatology</i> , 2017, 153, 1302.	2.0	28
72	Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1075-1079.	0.7	27

#	ARTICLE	IF	CITATIONS
73	Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14 ⁺ and CD16 ⁺ monocytes driving an innate immune response. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 627-636.	0.7	27
74	Validation Study of the AJCC Cancer Staging Manual, Eighth Edition, Staging System for Eyelid and Periocular Squamous Cell Carcinoma. <i>JAMA Ophthalmology</i> , 2019, 137, 537.	1.4	27
75	Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 504-507.	0.7	25
76	Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients. <i>Oncolmmunology</i> , 2018, 7, e1467856.	2.1	24
77	B7-H3 Expression in Merkel Cell Carcinoma-associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. <i>Clinical Cancer Research</i> , 2019, 25, 3455-3467.	3.2	24
78	Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma. <i>Cancers</i> , 2019, 11, 2031.	1.7	23
79	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1429-1441.	0.8	23
80	Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy. <i>Cancers</i> , 2019, 11, 754.	1.7	21
81	DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. <i>Clinical Cancer Research</i> , 2019, 25, 641-651.	3.2	21
82	Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. <i>Nature Communications</i> , 2021, 12, 4031.	5.8	21
83	High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma. <i>Oncolmmunology</i> , 2018, 7, e1475874.	2.1	20
84	Molecular characteristics and potential therapeutic targets in Merkel cell carcinoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 382-390.	1.0	19
85	Biological Validation of RNA Sequencing Data From Formalin-Fixed Paraffin-Embedded Primary Melanomas. <i>JCO Precision Oncology</i> , 2018, 2018, 1-19.	1.5	19
86	Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. <i>Modern Pathology</i> , 2020, 33, 496-513.	2.9	19
87	BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. <i>Human Pathology</i> , 2016, 50, 79-89.	1.1	18
88	Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 786-790.	0.7	18
89	Histological Features Associated With Vemurafenib-Induced Skin Toxicities. <i>American Journal of Dermatopathology</i> , 2014, 36, 557-561.	0.3	17
90	Histopathologic and mutational analysis of a case of blue nevus-like melanoma. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 776-780.	0.7	17

#	ARTICLE	IF	CITATIONS
91	Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 7585-7593.	3.2	17
92	Post-radiation vascular lesions of the breast. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 52-58.	0.7	17
93	Detection of mitotic figures and G2+ tumor nuclei with histone markers correlates with worse overall survival in patients with Merkel cell carcinoma. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 846-852.	0.7	16
94	Reed syndrome presenting with leiomyosarcoma. <i>JAAD Case Reports</i> , 2015, 1, 150-152.	0.4	16
95	Epithelial, non-melanocytic and melanocytic proliferations of the ocular surface. <i>Seminars in Diagnostic Pathology</i> , 2016, 33, 122-132.	1.0	16
96	TruSeq-Based Gene Expression Analysis of Formalin-Fixed Paraffin-Embedded (FFPE) Cutaneous T-Cell Lymphoma Samples: Subgroup Analysis Results and Elucidation of Biases from FFPE Sample Processing on the TruSeq Platform. <i>Frontiers in Medicine</i> , 2017, 4, 153.	1.2	16
97	Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1597-1605.	2.1	16
98	Impact of the 2009 (7th Edition) AJCC Melanoma Staging System in the Classification of Thin Cutaneous Melanomas. <i>BioMed Research International</i> , 2013, 2013, 1-7.	0.9	15
99	The evolving landscape of HPV-related neoplasia in the head and neck. <i>Human Pathology</i> , 2019, 94, 29-39.	1.1	15
100	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. <i>Nature Communications</i> , 2020, 11, 1839.	5.8	15
101	Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. <i>Oncotarget</i> , 2020, 11, 600-618.	0.8	15
102	T-Cell Receptor- $\gamma\delta$ in Gamma-Delta Phenotype Cutaneous T-Cell Lymphoma Can Be Accompanied by Atypical Expression of CD30, CD4, or TCR β F1 and an Indolent Clinical Course. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e195-e200.	0.2	14
103	Melanoma With Loss of BAP1 Expression in Patients With No Family History of BAP1-Associated Cancer Susceptibility Syndrome: A Case Series. <i>American Journal of Dermatopathology</i> , 2019, 41, 167-179.	0.3	14
104	T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2146-2156.e4.	0.3	14
105	Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 539-544.	0.7	13
106	Differential expression of CCR4 in primary cutaneous gamma/delta ($\gamma\delta$) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy. <i>Journal of Dermatological Science</i> , 2018, 89, 88-91.	1.0	13
107	High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. <i>Scientific Reports</i> , 2021, 11, 9043.	1.6	13
108	Primary cutaneous CD30 ⁺ lymphoproliferative disorders. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 767-782.	0.4	12

#	ARTICLE	IF	CITATIONS
109	Whole-exome sequencing for ocular adnexal sebaceous carcinoma suggests PCDH15 as a novel mutation associated with metastasis. <i>Modern Pathology</i> , 2020, 33, 1256-1263.	2.9	12
110	Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa177.	0.4	12
111	Use of clinical next-generation sequencing to identify melanomas harboring <i>SMARCB1</i> mutations. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 308-317.	0.7	11
112	HTLV-1-associated infective dermatitis demonstrates low frequency of FOXP3-positive T-regulatory lymphocytes. <i>Journal of Dermatological Science</i> , 2015, 77, 150-155.	1.0	11
113	Proliferation indices correlate with diagnosis and metastasis in diagnostically challenging melanocytic tumors. <i>Human Pathology</i> , 2016, 53, 73-81.	1.1	11
114	Merkel cell carcinoma with fingolimod treatment for multiple sclerosis: A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 12-14.	0.9	11
115	Clinical validity of a gene expression signature in diagnostically uncertain neoplasms. <i>Personalized Medicine</i> , 2020, 17, 361-371.	0.8	11
116	Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. <i>Cancer Medicine</i> , 2020, 9, 8650-8661.	1.3	11
117	Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2021, 37, e9-e13.	0.4	11
118	Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. <i>International Journal of Dermatology</i> , 2019, 58, 1045-1052.	0.5	11
119	Immunohistochemical markers informing the diagnosis of sebaceous carcinoma and its distinction from its mimics: Adipophilin and factor XIIIa to the rescue?. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 29-32.	0.7	10
120	Unusual cutaneous metastatic carcinoma. <i>Annals of Diagnostic Pathology</i> , 2019, 43, 151399.	0.6	10
121	BAP-1 Expression Status by Immunohistochemistry in Cellular Blue Nevus and Blue Nevus-like Melanoma. <i>American Journal of Dermatopathology</i> , 2020, 42, 313-321.	0.3	10
122	iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation. <i>Frontiers in Oncology</i> , 2021, 11, 631766.	1.3	10
123	The tumor immune contexture of salivary duct carcinoma. <i>Head and Neck</i> , 2021, 43, 1213-1219.	0.9	10
124	Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. <i>Clinical Cancer Research</i> , 2021, 27, 5072-5083.	3.2	10
125	Giemsa is the optimal counterstain for immunohistochemical detection of <i>BRAF V600E</i> mutation status in pigmented melanomas. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 722-724.	0.7	9
126	Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma. <i>Oncotarget</i> , 2017, 8, 115140-115152.	0.8	9

#	ARTICLE	IF	CITATIONS
127	Predictors of Local Recurrence for Eyelid Sebaceous Carcinoma: Questionable Value of Routine Conjunctival Map Biopsies for Detection of Pagetoid Spread. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2019, 35, 419-425.	0.4	9
128	Measurement of Tumor Thickness in Cutaneous Squamous Cell Carcinomas: Do the Different Methods Provide Better Prognostic Data?. <i>American Journal of Dermatopathology</i> , 2020, 42, 337-342.	0.3	9
129	Cutaneous metastasis from anaplastic thyroid carcinoma exhibiting exclusively a spindle cell morphology. A case report and review of literature. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 252-257.	0.7	8
130	Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma. <i>Human Pathology</i> , 2017, 59, 48-54.	1.1	8
131	Intratumoral and peritumoral lymphovascular invasion detected by D2-40 immunohistochemistry correlates with metastasis in primary cutaneous Merkel cell carcinoma. <i>Human Pathology</i> , 2018, 77, 98-107.	1.1	8
132	Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 954-959.	0.7	8
133	Prognostic significance of acral lentiginous histologic type in T1 melanoma. <i>Modern Pathology</i> , 2021, 34, 572-583.	2.9	8
134	Cutaneous histoplasmosis with prominent parasitization of epidermal keratinocytes: report of a case. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 1155-1160.	0.7	7
135	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>BRAF</i> -mutated melanoma. <i>Oncology</i> , 2021, 10, 1992880.	2.1	7
136	Granulomatous changes associated with pigmented purpuric dermatosis. <i>Cutis</i> , 2014, 94, 197-202.	0.4	7
137	Middle cerebral artery territory infarct due to <i>Cryptococcus</i> infection. <i>Diagnostic Cytopathology</i> , 2015, 43, 632-634.	0.5	6
138	Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report. <i>Immunotherapy</i> , 2020, 12, 1213-1219.	1.0	6
139	TERT amplification but not activation of canonical Wnt/ β -catenin pathway is involved in acral lentiginous melanoma progression to metastasis. <i>Modern Pathology</i> , 2020, 33, 2067-2074.	2.9	6
140	Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. <i>Oncotarget</i> , 2019, 10, 4703-4718.	0.8	6
141	Primary orbital melanoma in association with cellular blue nevus. <i>Digital Journal of Ophthalmology: DJO</i> , 2014, 20, 35-40.	0.2	6
142	Aberrant expression of <i>FLI1</i> in melanoma. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 790-793.	0.7	5
143	Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 545-549.	0.7	5
144	Angiotropism in recurrent cutaneous squamous cell carcinoma: Implications for regional tumor recurrence and extravascular migratory spread. <i>Journal of Cutaneous Pathology</i> , 2018, 46, 152-158.	0.7	5

#	ARTICLE	IF	CITATIONS
145	Spitzoid melanoma with histopathological features of <i>ALK</i> gene rearrangement exhibiting <i>ALK</i> copy number gain: a novel mechanism of <i>ALK</i> activation in spitzoid neoplasia. <i>British Journal of Dermatology</i> , 2019, 180, 404-408.	1.4	5
146	Immunohistochemical and Molecular Features of Melanomas Exhibiting Intratumor and Intertumor Histomorphologic Heterogeneity. <i>Cancers</i> , 2019, 11, 1714.	1.7	5
147	Association of T and N Categories of the American Joint Commission on Cancer, 8th Edition, With Metastasis and Survival in Patients With Orbital Sarcoma. <i>JAMA Ophthalmology</i> , 2020, 138, 374.	1.4	5
148	Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 377-383.	1.4	5
149	Role of Radiotherapy in Aggressive Digital Papillary Adenocarcinoma. <i>Annals of Clinical and Laboratory Science</i> , 2016, 46, 222-4.	0.2	5
150	Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis fungoides-like morphologic and molecular features. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 872-877.	0.7	4
151	Lichen planus related to transforming growth factor beta inhibitor in a patient with metastatic chondrosarcoma: a case report. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 490-493.	0.7	4
152	Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 674-679.	0.7	4
153	Capecitabine-induced leukocytoclastic vasculitis under neoadjuvant chemotherapy for locally advanced colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, E40-3.	0.6	4
154	Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers. <i>Annals of Diagnostic Pathology</i> , 2018, 34, 151-154.	0.6	3
155	Melanoma coexisting with solar elastosis: a potential pitfall in the differential diagnosis between nevus and melanoma. <i>Human Pathology</i> , 2019, 84, 270-274.	1.1	3
156	Langerhans cell sarcoma involving skin and showing epidermotropism: A comprehensive review. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 547-557.	0.7	3
157	Loss of dimethylated H3K27 (H3K27me2) expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST): An immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic tumors. <i>Annals of Diagnostic Pathology</i> , 2022, 59, 151967.	0.6	3
158	Resistant mechanisms to BRAF inhibitor PLX4032 in melanoma. <i>Expert Review of Dermatology</i> , 2011, 6, 355-357.	0.3	2
159	Pruritic arthropod bite-like papules in T-cell large granular lymphocytic leukaemia and chronic myelomonocytic leukaemia. <i>Clinical and Experimental Dermatology</i> , 2018, 43, 449-453.	0.6	2
160	Update on sebaceous neoplasia: the morphologic spectrum and molecular genetic drivers of carcinoma. <i>Diagnostic Histopathology</i> , 2019, 25, 102-109.	0.2	2
161	Prognostic Significance of Nonsolid Microscopic Metastasis in Merkel Cell Carcinoma Sentinel Lymph Nodes. <i>American Journal of Surgical Pathology</i> , 2019, 43, 907-919.	2.1	2
162	Cutaneous neoplasms composed of melanoma and carcinoma: A rare but important diagnostic pitfall and review of the literature. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 36-46.	0.7	2

#	ARTICLE	IF	CITATIONS
163	Perianal condylomata lata mimicking carcinoma. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 209-214.	0.7	2
164	A 60-year-old woman with an asymptomatic left lacrimal gland mass found incidentally. <i>Digital Journal of Ophthalmology: DJO</i> , 2017, 23, 118-120.	0.2	2
165	Primary Cutaneous Peripheral T-Cell Lymphoma in a Sporotrichoid Pattern: A Case Report. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 568-571.	0.6	1
166	Without Missing a Beat: Absence of Cilia Informs the Diagnosis of Histopathologically Challenging Spitzoid Melanocytic Neoplasms. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1320-1323.	0.3	1
167	BAP1-inactivated melanocytic tumor with preserved BAP1 expression? Morphology to the rescue!. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 459-461.	0.7	1
168	Cutaneous adnexal carcinosarcoma: Immunohistochemical and molecular evidence of epithelial mesenchymal transition. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 526-534.	0.7	1